Rising rates appear concentrated in hormone receptor–positive disease, aligning with later age at first birth, fewer ...

Improvements seen in PFS, OS with Dato-DXd for previously untreated, locally recurrent inoperable or metastatic TNBC.

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

Researchers at The University of Texas MD Anderson Cancer Center have identified a key enzyme—RNase H2—that helps ...

Now, a global clinical trial has shown promising results in extending survival for patients with TNBC. The TROPION-Breast02 trial tested a high-tech treatment called datopotamab deruxtecan (Dato-DXd), ...

Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical ...

Triple Negative Breast Cancer (TNBC) is one of the most aggressive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks estrogen, progesterone, and HER2 receptors ...

Two University of Kentucky Markey Cancer Center researchers have each received a Research Scholar Grant from the American ...

Expression of α-basic-crystallin – Expressed in approximately 50% 33 Increased versus other intrinsic types * BLBC—variously defined (that is not restricted to tumors defined on gene-expression ...

Neoadjuvant, but not adjuvant, chemoimmunotherapy significantly improved key outcomes in certain patients with early breast cancer, according to a meta-analysis involving more than 5,000 patients.